30 October 2015

FMD K&L Inc. Expands Operations to Japan to Support Client Needs at a Local Level

Tokyo, Japan; 29 October, 2015 – FMD K&L Inc., a privately owned Contract Research Organization (CRO) with headquarters in the US and China, recently expanded their operations to Japan to support client needs at a local level.

As we continue to grow our footprint throughout the globe, we put the needs of our clients first. “We have anticipated that our clients would need CDISC conversion services in Japan given the new regulatory changes that are quickly approaching in the near future,” said Dr. Dan Zhang, CEO. “With our expertise on CDISC compliance and our extensive experience on supporting our clients for regulatory submissions we are able to provide high quality services to suit their needs.”

This office will support client needs for a range of services including data management, biostatistics, statistical programming, clinical data interchange standards consortium (CDISC) compliant eSubmission, regulatory services, and clinical operations.  We will also assist Japanese clients who would like to enter the China market by offering clinical project services including regulatory affairs, project management, clinical site monitoring, and site management.

Although we have just established our footprint in Japan, we have extensive experience working on projects in this region.  This in turn makes us a trusted partner that will utilize our expertise to provide cost‐effective and high quality work for your next project.

About FMD K&L Inc.

FMD K&L Inc. is a Contract Research Organization (CRO) offering data management, biostatistics, statistical programming, CDISC compliant eSubmission, drug safety, and medical writing services to the pharmaceutical, biotechnology, and medical device industries worldwide.  In addition, we provide regulatory affairs in China and South East Asia, and clinical operations in mainland China, Hong Kong, Taiwan, South Korea, and Europe. We continuously strive to raise the standard of excellence through accuracy and efficiency. This results in high quality output to get our client’s drug or medical product approved faster and to improve the lives of patients.

                                                           #  #  #


US Contact                                                                       Japan Contact

Catherine Ditzler                                                             Sanae Fujita (藤⽥ 早苗)

Marketing Manager                                                         Director of Business Development

1‐215‐283‐6035                                                              81‐3‐6228‐7360                                        sanae.fujita@fountain‐